Executive Summary
Congenital adrenal hyperplasia (CAH) remains one of the most challenging endocrine disorders to manage despite decades of therapeutic advances. Current treatment relies primarily on lifelong glucocorticoid replacement, often administered at supraphysiologic doses to suppress excessive adrenocorticotropic hormone (ACTH) secretion and adrenal androgen production. While effective in preventing adrenal crisis, chronic glucocorticoid therapy is associated with obesity, osteoporosis, diabetes, cardiovascular disease, impaired growth, infertility, reduced quality of life, and increased long-term morbidity.
Recent therapeutic innovation has shifted from treating downstream hormone excess toward targeting the underlying endocrine physiology responsible for androgen overproduction. Crinetics Pharmaceuticals' investigational agent, atumelnant, represents the first oral selective ACTH receptor (MC2R) antagonist to enter Phase 3 clinical development. By directly blocking ACTH signaling at the adrenal cortex, atumelnant offers the potential to normalize adrenal androgen production while allowing glucocorticoid replacement doses to return toward physiologic levels. Early Phase 2 studies demonstrated substantial reductions in androstenedione, 17-hydroxyprogesterone, and other androgen biomarkers together with encouraging safety and tolerability.
While these scientific advances are promising, the eventual market leader in CAH may ultimately be determined by more than clinical efficacy alone. Physician adoption, patient identification, market access, Centers of Excellence engagement, and long-term commercial execution are likely to play equally important roles in defining success.
This review examines the current treatment landscape, competing therapeutic approaches, the scientific rationale supporting ACTH receptor antagonism, published clinical evidence for atumelnant, and the commercial factors likely to influence the next generation of CAH care.
Congenital Adrenal Hyperplasia
Approximately 95% of classic CAH results from mutations in the CYP21A2 gene, causing 21-hydroxylase deficiency.
The disease results in:
- Cortisol deficiency
- Elevated ACTH
- Adrenal hyperplasia
- Excess androgen production
- Variable aldosterone deficiency
Patients may experience:
- Virilization
- Infertility
- Menstrual abnormalities
- Testicular adrenal rest tumors (TARTs)
- Adrenal enlargement
- Poor quality of life
- Lifelong dependence on steroid replacement
Although rare, CAH requires lifelong specialist care and remains associated with substantial clinical and psychosocial burden.
The Current Standard of Care
Management has changed relatively little over the past five decades.
Treatment continues to rely primarily on glucocorticoid replacement using:
- Hydrocortisone
- Prednisone
- Dexamethasone
These therapies perform two critical but competing functions:
- Replace deficient cortisol
- Suppress excessive ACTH production
Unfortunately, adequate ACTH suppression often requires glucocorticoid doses substantially above physiologic replacement, creating one of the central therapeutic challenges in CAH management.
The Cost of Supraphysiologic Steroid Therapy
Long-term exposure to supraphysiologic glucocorticoids has been associated with:
- Weight gain
- Hypertension
- Diabetes mellitus
- Osteoporosis
- Growth suppression
- Mood disorders
- Reduced fertility
- Increased cardiovascular risk
Clinicians have long faced the difficult balance of controlling androgen excess while minimizing treatment-related complications.
Current FDA-Approved Therapies
Glucocorticoids
Glucocorticoids remain the cornerstone of therapy.
Advantages
- Inexpensive
- Familiar to clinicians
- Effective cortisol replacement
Limitations
- Cannot selectively suppress ACTH
- Significant long-term toxicity when used above physiologic replacement
Crenessity® (Crinecerfont)
Neurocrine Biosciences introduced the first non-steroidal ACTH pathway therapy through CRF1 receptor antagonism. By reducing pituitary ACTH secretion upstream of the adrenal gland, the therapy is intended to reduce supraphysiologic glucocorticoid requirements while maintaining androgen control.
Strengths
- First targeted non-steroidal therapy
- Reduces ACTH production
- Enables glucocorticoid reduction
Potential Limitations
- Depends upon adequate suppression of pituitary ACTH
- Does not directly block ACTH signaling at the adrenal cortex
The Atumelnant Mechanism
Unlike CRF1 antagonists, atumelnant blocks the ACTH receptor itself.
ACTH → MC2R receptor → Cortisol and Androgen Production
Atumelnant selectively antagonizes the melanocortin-2 receptor (MC2R) located on the adrenal cortex, preventing ACTH from stimulating excess adrenal steroid production.
Potential advantages include:
- Direct adrenal targeting
- Reduction in androgen production despite persistent ACTH
- Potential for physiologic glucocorticoid replacement
- Once-daily oral administration
Published Clinical Data
Across published Phase 2 studies investigators reported:
Hormonal Control
Mean reductions in androstenedione included:
- 40 mg: 58%
- 80 mg: 70%
- 120 mg: 80%
Several participants achieved normalization of androgen biomarkers.
Glucocorticoid Reduction
Approximately 88% of participants in one cohort reached physiologic glucocorticoid replacement doses while maintaining androgen control.
Clinical Improvements
Reported findings included:
- Reduced adrenal volume
- Resumption of normal menstrual cycles in some women
- Sustained reductions in 17-hydroxyprogesterone
- Reduced 11-oxygenated androgens
- Stable disease control during glucocorticoid reduction
Safety
Published studies have reported:
- No treatment-related serious adverse events
- Generally mild adverse events
- Favorable overall tolerability
Ongoing Clinical Development
The adult CALM-CAH Phase 3 trial is evaluating whether atumelnant can:
- Normalize adrenal androgen production
- Reduce glucocorticoid doses toward physiologic replacement
- Improve long-term disease control
The pediatric BALANCE-CAH Phase 2/3 study reflects the importance of reducing steroid burden early in life, when growth, bone development, and reproductive health may be most significantly affected.
Commercial Realities That Will Determine Success
Positive Phase 3 data represent an important milestone—but not the finish line.
History has repeatedly shown that successful commercialization requires substantially more than regulatory approval.
Diagnosis Remains the Largest Barrier
Even the most effective therapy cannot benefit patients who remain undiagnosed or are diagnosed years after symptoms begin.
Many individuals experience prolonged diagnostic journeys before reaching endocrinologists with expertise in CAH. Improving disease recognition, referral pathways, and earlier diagnosis will remain essential components of long-term commercial success.
Centers of Excellence Will Shape Early Adoption
Unlike common chronic diseases, CAH care is concentrated within a relatively small number of pediatric and adult endocrine Centers of Excellence.
These institutions influence treatment guidelines, publish clinical evidence, train future endocrinologists, and frequently establish standards that extend well beyond their own patient populations.
Early scientific engagement with these centers is likely to influence national adoption patterns.
Market Access Will Define Uptake
Even highly differentiated therapies must demonstrate value beyond laboratory improvements.
Payers will increasingly evaluate whether treatment leads to measurable reductions in long-term complications associated with chronic glucocorticoid exposure, including metabolic disease, infertility, reduced bone health, and hospital utilization.
The commercial discussion is therefore likely to focus as much on lifetime health outcomes as on endocrine biomarkers.
Physician Behavior Changes Gradually
Endocrinologists have relied on glucocorticoids for decades.
Introducing a fundamentally different treatment paradigm requires more than strong clinical trial results.
Long-term confidence will likely develop through:
- Continued clinical evidence
- Real-world outcomes
- Updated treatment guidelines
- Peer experience
- Ongoing physician education
Commercial adoption should be expected to evolve over several years rather than immediately following approval.
Geography Continues to Influence Patient Access
Many patients with CAH do not live near specialized endocrine centers.
Travel requirements, referral delays, limited specialist availability, and fragmented transitions from pediatric to adult endocrinology continue to create barriers that innovative therapies alone cannot overcome.
Companies that develop effective physician education, referral support, and patient access strategies may create meaningful competitive advantages beyond the product itself.
Conclusion
Congenital adrenal hyperplasia is entering one of the most important periods of therapeutic innovation in its history.
Targeted endocrine therapies—including CRF1 antagonists and investigational ACTH receptor antagonists—offer the potential to reduce long-standing dependence on supraphysiologic glucocorticoids while improving disease control and quality of life.
Atumelnant's Phase 2 results are encouraging and support continued evaluation in Phase 3 clinical trials. Whether these findings ultimately translate into durable clinical benefit remains the key scientific question.
Equally important, however, will be how successfully future therapies are integrated into clinical practice. Physician confidence, patient identification, Centers of Excellence engagement, market access, and long-term evidence generation will all influence adoption.
Scientific innovation may open the door to a new era in CAH treatment. Commercial execution will determine who ultimately leads it.
Executive Insight
The introduction of targeted therapies represents one of the most significant advances in congenital adrenal hyperplasia management in decades. Yet history has consistently demonstrated that scientific innovation alone does not ensure commercial success.
For companies developing next-generation CAH therapies, the challenge extends well beyond achieving positive Phase 3 results. Success will depend upon identifying appropriate patients, building confidence among endocrinologists, generating long-term outcomes data, navigating increasingly complex payer requirements, and establishing meaningful partnerships with the relatively small number of Centers of Excellence that influence national clinical practice.
As the therapeutic landscape evolves, the competitive advantage may ultimately belong not only to the company with the most effective therapy, but to the organization that best integrates clinical evidence, physician education, patient access, market access strategy, and commercial execution into a coherent long-term strategy.
For biotechnology companies preparing for launch, commercial readiness should begin well before regulatory approval. In rare diseases such as CAH, the companies that invest early in building scientific partnerships, understanding referral pathways, addressing access barriers, and preparing the healthcare ecosystem are often best positioned to translate scientific innovation into meaningful patient impact.
